Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 10/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 9/20 | 0.59 |
| ▸ | ADORA2A | P29274 | 9/20 | 0.59 |
| ▸ | MAOB | P27338 | 4/20 | 0.55 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MIF | P14174 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6490869 | 0.84 | NPC1 (0.56) | ADORA3ADORA1ADORA2AMAOBGPR35 | |
| SCHEMBL6478883 | 0.81 | ADORA3 (0.60) | ADORA3ADORA1ADORA2AMAOBGPR35 | |
| SCHEMBL6490859 | 0.77 | GPR35 (0.76) | MAOBGPR35ALDH1A1 | |
| SCHEMBL8121046 | 0.75 | ADORA2A (1.00) | ADORA3ADORA1ADORA2AMAOBNPC1 | |
| SCHEMBL6480410 | 0.72 | RAB9A (0.53) | ADORA3ADORA1ADORA2AMAOBNPC1 | |
| SCHEMBL1609267 | 0.72 | GPR35 (0.51) | GPR35 | |
| SCHEMBL8108312 | 0.71 | ADORA2A (0.70) | ADORA3ADORA1ADORA2AMAOBKDM4E | |
| SCHEMBL1706855 | 0.70 | PON1 (0.72) | ADORA3ADORA1ADORA2AMAOBGPR35 | |
| SCHEMBL3364697 | 0.69 | GPR35 (0.45) | GPR35PKM | |
| SCHEMBL6480420 | 0.69 | ADORA3 (0.54) | ADORA3ADORA1ADORA2AMAOBGPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6951870-B2 | Coumarin derivatives with COMT inhibiting activity | ORION CORPORATION (FI) | 2005-10-04 | — | — | US | disclosed |
| CN-1199963-C | Coumarin derivatives with COMT inhibiting activity | ORION CORP (FI) | 2005-05-04 | — | — | CN | disclosed |
| US-20040110750-A9 | Coumarin derivatives with comt inhibiting activity | ORION CORPORATION (FI) | 2004-06-10 | — | — | US | disclosed |
| EP-1301503-B1 | COUMARIN DERIVATIVES WITH COMT INHIBITING ACTIVITY | ORION CORP (FI) | 2004-02-25 | — | — | EP | disclosed |
| US-20030186975-A1 | Coumarin derivatives with comt inhibiting activity | PYSTYNEN JARMO (FI) | 2003-10-02 | — | — | US | disclosed |
| CN-1440399-A | Coumarin derivatives with COMT inhibiting activity | ORION CORP (FI) | 2003-09-03 | — | — | CN | disclosed |
| EP-1301503-A1 | COUMARIN DERIVATIVES WITH COMT INHIBITING ACTIVITY | ORION CORPORATION (FI) | 2003-04-16 | — | — | EP | disclosed |
| WO-2002002548-A1 | COUMARIN DERIVATIVES WITH COMT INHIBITING ACTIVITY | ORION CORPORATION (FI) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110750-A9 | Coumarin derivatives with comt inhibiting activity | COMT, CYP1A1, CYP2D6 | ADORA3 2152/4885ADORA1 1712/4885ADORA2A 3398/4885 |
| US-20030186975-A1 | Coumarin derivatives with comt inhibiting activity | COMT, CYP1A1, CYP2D6 | ADORA3 2152/4885ADORA1 1712/4885ADORA2A 3398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.